GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Qualified Persons Adapt to Industry 4.0 with Certification by Design Framework for Agile Batch Release

by GOAI
Share To

The integration of advanced manufacturing technologies is transforming pharmaceutical production processes, prompting a shift in the role of Qualified Persons (QPs). Traditionally responsible for reviewing documentation, QPs are now required to adapt to a digital environment characterized by complex data ecosystems, real-time analytics, and automated control systems. A new framework called “Certification by Design” outlines how QPs can maintain compliance while enabling agile and science-based batch release practices in alignment with Industry 4.0 advancements.

This approach emphasizes the need for QPs to develop digital fluency and leadership skills to effectively oversee modernized production systems. The framework addresses challenges posed by increased automation and data-driven decision-making, providing strategies for ensuring regulatory compliance without compromising efficiency or innovation. By leveraging real-time analytics and automated controls, QPs can streamline certification processes while maintaining rigorous quality standards in pharmaceutical manufacturing.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top